Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Omental band induced bowel ischemia following combination immunotherapy in a patient with renal cell cancer.

Irish medical journal·2026
Same author

Jet ventilation.

BJA education·2025
Same author

Female cricket pace bowling: kinematic and anthropometric relationships with ball release speed.

South African journal of sports medicine·2024
Same author

Interpreting evidence on 'failed intubation': are we losing airways or losing our minds?

Anaesthesia·2024
Same author

A case report on concomitant reversible cerebral vasoconstriction syndrome and transient global amnesia.

Cortex; a journal devoted to the study of the nervous system and behavior·2023
Same author

The effect of high-flow nasal oxygen flow rate on gas exchange in apnoeic patients: a randomised controlled trial.

Anaesthesia·2023

Related Experiment Video

Updated: Sep 27, 2025

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.3K

Radium-223 in the Treatment of Metastatic Castrate-Resistant Prostate Cancer.

N Peters1, R M Bambury1, D G Power1

  • 1Department of Medical Oncology, Cork University Hospital.

Irish Medical Journal
|April 13, 2022
PubMed
Summary

Radium-223 (Ra-223) offers a moderately tolerated palliative treatment for Irish men with metastatic castrate-resistant prostate cancer (mCRPC). Real-world outcomes show improved pain scores and a median overall survival of 7 months.

More Related Videos

A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy PRRT: 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods
09:49

A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy PRRT: 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods

Published on: April 24, 2020

10.1K
Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

20.5K

Related Experiment Videos

Last Updated: Sep 27, 2025

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.3K
A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy PRRT: 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods
09:49

A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy PRRT: 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods

Published on: April 24, 2020

10.1K
Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

20.5K

Area of Science:

  • Oncology
  • Nuclear Medicine
  • Radiopharmaceutical Therapy

Background:

  • Metastatic castrate-resistant prostate cancer (mCRPC) is a significant clinical challenge.
  • Radium-223 (Ra-223) is an alpha-emitting radiopharmaceutical approved for mCRPC treatment.
  • Real-world data on Ra-223 use in Ireland was previously undescribed.

Purpose of the Study:

  • To describe the real-world outcomes of Ra-223 treatment in Irish patients with mCRPC.
  • To evaluate treatment tolerability, survival, and factors influencing outcomes.

Main Methods:

  • Retrospective analysis of 54 mCRPC patients treated with Ra-223 from September 2016 to March 2019.
  • Data collection included demographics, prior treatments, toxicities, and survival outcomes.
  • Overall survival (OS) and progression-free survival (PFS) analyzed using Kaplan-Meier methods.

Main Results:

  • Median patient age was 75 years, with a median of 2 prior systemic treatments.
  • Median OS was 7 months; 37% completed all 6 planned Ra-223 cycles.
  • Fatigue was the most common toxicity (52%); 76% of patients with pain requiring opioids reported improvement.

Conclusions:

  • Radium-223 is a moderately well-tolerated palliative option for Irish men with mCRPC.
  • Good ECOG status, fewer bone metastases, normal alkaline phosphatase, and chemotherapy naivety were associated with improved OS.
  • Real-world data supports the use of Ra-223 in this patient population.